Gut Microbiota-Based Immunotherapy: Engineered <i>Escherichia coli</i> Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer

Gut Microbiota-Based Immunotherapy: Engineered <i>Escherichia coli</i> Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer

<i>Background and Objectives</i>: The administration of oral vaccines offers a potential strategy for cancer immunotherapy; yet, the development of effective platforms continues to pose a difficulty. This study examines <i>Escherichia coli</i> Nissle 1917 (EcN) as a microbial...

Full description

Saved in:
Bibliographic Details
Main Authors: Idris Vruzhaj, Marta Gambirasi, Davide Busato, Aurora Giacomin, Giuseppe Toffoli, Amin Safa
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Medicina
Subjects:
oral vaccine delivery
Glypican-1
immunotherapy
<i>Escherichia coli</i> Nissle 1917
pancreatic cancer vaccines
Online Access:https://www.mdpi.com/1648-9144/61/4/633
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1648-9144/61/4/633

Similar Items